MCDG News CytoCore Announces Results from Annual Shareholders Meeting
CHICAGO--(BUSINESS WIRE)--June 22, 2006--CytoCore, Inc. (OTCBB:MCDG) announced the following results from their annual shareholders meeting held on Friday June 16th. First, shareholders voted to officially change the name of the company to CytoCore, Inc. This name change application is being submitted to the State registrar where the Company is incorporated. Following the State's acceptance of the name change, the Company will be applying to NASDAQ for a change in the Company's stock symbol. Secondly, the Board of Directors was elected to serve another term.
The presentation given and information discussed at the meeting is available for download at the Company's web site. The meeting was well attended by shareholders.
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
